Sudden infant death syndrome · term and preterm neonates with hyperbilirubinaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival: all participants compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival in people with central nervous system disease · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall adverse events · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in overall adverse events compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with any cytotoxic chemotherapy (low certainty).
1 finding from 1 review
Overall survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower overall survival compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor probably leads to higher overall response rate compared with any cytotoxic chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Change in FEV1 % predicted at end of antibiotic course: absolute post‐treatment values · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in FEV1 % predicted at end of antibiotic course: absolute… compared with combination intravenous anti‐pseudomonal antibiotic therapy (low certainty).
1 finding from 1 review
Time to next course of antibiotics  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
Quality of life · adults and children with cystic fibrosis
1 finding from 1 review
Change in sputum P aeruginosa density at end of treatment (cfu/g) · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in sputum P aeruginosa density at end of treatment (cfu/g) compared with combination intravenous anti‐pseudomonal antibiotic therapy (moderate certainty).
2 findings from 1 review
Need for extra treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival (Duration of · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival (Duration of (high certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 1‐year survival rate  · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 1‐year survival rate  (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 2‐year survival rate · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 2‐year survival rate (moderate certainty).
1 finding from 1 review